Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure

Abuissa, 2008, The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection, Diabetes Obes Metab, 10, 1157

Campbell, 2006, A review of perindopril in the reduction of cardiovascular events, Vasc Health Risk Manag, 2, 117, 10.2147/vhrm.2006.2.2.117

Dagenais, 2006, Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials, Lancet, 368, 581, 10.1016/S0140-6736(06)69201-5

Dendorfer, 2005, ACE inhibitors and angiotensin II receptor antagonists, Handb Exp Pharmacol, 170, 407, 10.1007/3-540-27661-0_15

Fox, 2003, Lancet, 362, 782, 10.1016/S0140-6736(03)14974-4

Holecki, 2011, Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure - are they important for doctors?, Pharmacol Rep, 63, 740, 10.1016/S1734-1140(11)70586-2

Kher, 2004, Pathobiology of atherosclerosis – a brief review, Semin Thromb Hemost, 30, 665, 10.1055/s-2004-861509

Kothari, 2003, Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications, J Thromb Thrombolysis, 15, 217, 10.1023/B:THRO.0000011379.68077.64

Krysiak, 2011, Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia, Am J Cardiol, 107, 1010, 10.1016/j.amjcard.2010.11.023

Krysiak, 2011, Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure, Pharmacol Rep, 63, 1151, 10.1016/S1734-1140(11)70634-X

Krysiak, 2011, Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients, Pharmacol Rep, 63, 95, 10.1016/S1734-1140(11)70403-0

Krysiak, 2008, Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease, Pharmacol Rep, 60, 514

Krysiak, 2011, The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis, J Clin Endocrinol Metab, 96, 2206, 10.1210/jc.2010-2986

Krysiak, 2010, The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease, Endokrynol Pol, 61, 280

Krysiak, 2010, The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease, Endokrynol Pol, 61, 683

Krysiak, 2010, Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances, Pharmacol Rep, 62, 120, 10.1016/S1734-1140(10)70249-8

McFarlane, 2009, Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials, Expert Rev Cardiovasc Ther, 7, 1363, 10.1586/erc.09.115

Naftilan, 1994, Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth, Curr Opin Nephrol Hypertens, 3, 218, 10.1097/00041552-199403000-00014

Neultel, 2004, Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function, J Hum Hypertens, 18, 599, 10.1038/sj.jhh.1001714

Okopień, 2005, Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary hypercholesterolemia, J Cardiovasc Pharmacol, 45, 314, 10.1097/01.fjc.0000156821.50457.32

Okopień, 2005, Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates, J Cardiovasc Pharmacol, 46, 377, 10.1097/01.fjc.0000175455.46245.c8

2001, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack, Lancet, 358, 1033, 10.1016/S0140-6736(01)06178-5

Ridker, 2007, Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity, Nutr Rev, 65, S253, 10.1301/nr.2007.dec.S253-S259

Sironi, 2005, Antiinflammatory properties of drugs acting on the reninangiotensin system, Drugs Today, 41, 609, 10.1358/dot.2005.41.9.899613

Tedgui, 2006, Cytokines in atherosclerosis: pathogenic and regulatory pathways, Physiol Rev, 86, 515, 10.1152/physrev.00024.2005

Wilson, 2009, Macrophages: promising targets for the treatment of atherosclerosis, Curr Vasc Pharmacol, 7, 234, 10.2174/157016109787455635

Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342, 145